These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36280238)

  • 41. Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteria.
    Kuriya B; Sun Y; Boire G; Haraoui B; Hitchon C; Pope JE; Thorne JC; Keystone EC; Bykerk VP;
    J Rheumatol; 2012 Jun; 39(6):1155-8. PubMed ID: 22505708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment target.
    Legrand J; Kirchgesner T; Sokolova T; Vande Berg B; Durez P
    Joint Bone Spine; 2019 Oct; 86(5):594-599. PubMed ID: 30928534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis.
    Mueller RB; Schiff M; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; von Kempis J;
    Clin Rheumatol; 2015 Jan; 34(1):51-9. PubMed ID: 25024096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study.
    Zhu H; Li R; Da Z; Bi L; Li X; Li Y; Liu C; Zhang F; Li Z; Liu X; Zhang Z; Sun L; Wang Y; Zhang W; Jiang Q; Chen J; Chen Q; Li Z; Wu L; Qi W; Xu J; Cui X; Wang X; Li L; Leng X; Wang G; Zhao D; Jiang L; He D; Liu X; Li L; Fang Y; Huang C; Wu H; Hu S; Li Q; Song H; Xiao W; Gong L; Zhang L; Li X; Li Z; Su Y
    Clin Rheumatol; 2018 Mar; 37(3):597-605. PubMed ID: 29116543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission.
    Ben Abdelghani K; Miladi S; Makhlouf Y; Fazaa A; Sallemi M; Souebni L; Ouenniche K; Kassab S; Chekili S; Ben Salem K; Zakraoui L; Laatar A
    Sultan Qaboos Univ Med J; 2022 Nov; 22(4):554-560. PubMed ID: 36407714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis.
    Thiele K; Huscher D; Bischoff S; Späthling-Mestekemper S; Backhaus M; Aringer M; Kohlmann T; Zink A;
    Ann Rheum Dis; 2013 Jul; 72(7):1194-9. PubMed ID: 22915625
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol.
    Paulshus Sundlisæter N; Olsen IC; Aga AB; Hammer HB; Uhlig T; van der Heijde D; Kvien TK; Lillegraven S; Haavardsholm EA;
    Rheumatology (Oxford); 2018 Nov; 57(11):2022-2031. PubMed ID: 30053199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response criteria for rheumatoid arthritis in clinical practice: how useful are they?
    Gülfe A; Geborek P; Saxne T
    Ann Rheum Dis; 2005 Aug; 64(8):1186-9. PubMed ID: 15760931
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
    Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP
    Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
    Combe B; Allanore Y; Alten R; Caporali R; Durez P; Iannone F; Nurmohamed MT; Toumi M; Lee SJ; Kwon TS; Noh J; Park G; Yoo DH
    Arthritis Res Ther; 2021 Apr; 23(1):119. PubMed ID: 33863352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions.
    Studenic P; Smolen JS; Aletaha D
    Ann Rheum Dis; 2012 Oct; 71(10):1702-5. PubMed ID: 22736085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden.
    Einarsson JT; Willim M; Ernestam S; Saxne T; Geborek P; Kapetanovic MC
    Rheumatology (Oxford); 2019 Feb; 58(2):227-236. PubMed ID: 29538755
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
    Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis.
    Messelink MA; den Broeder AA; Marinelli FE; Michgels E; Verschueren P; Aletaha D; Tekstra J; Welsing PMJ
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37116986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
    Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
    Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
    Smolen JS; Breedveld FC; Schiff MH; Kalden JR; Emery P; Eberl G; van Riel PL; Tugwell P
    Rheumatology (Oxford); 2003 Feb; 42(2):244-57. PubMed ID: 12595618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.